Efficacy And Safety of Myo Inositol in The Treatment of Polycystic Ovary Syndrome Patients Comparison with Metformin
Karmoker CR1*, Khatun A2, Sarkar AC3
DOI:https://doi.org/10.17511/joog.2025.i01.03
1* Chandona Rani Karmoker, Medical Officer, UHC, Charghat, Rajshahi, Bangladesh.
2 Amena Khatun, Medical Officer, Chapainawabganj Sadar Hospital, Chapainawabganj, Bangladesh.
3 Arghya Chandra Sarkar, ICU Specialist, Lab Aid Cardiac Hospital, Dhaka, Bangladesh.
Background: In polycystic ovary syndrome (PCOS), changes in physical appearance, e., weight gain, hirsutism, menstrual disturbances and infertility result in reduced quality of life. Metformin and Myo-inositol, being insulin sensitisers, improve biochemical, clinical and reproductive parameters in PCOS women. This study was done to compare the efficacy and safety of Myo-inositol versus Metformin among PCOS women.
Methodology: This open-label randomised control trial was conducted over 1 year in the Department of Gynaecology & Obstetrics, Rajshahi Medical College Hospital, Rajshahi. A total of 100 women with polycystic ovarian syndrome were enrolled and randomly (by simple lottery method) divided into two treatment groups: group A (Tab. Myo-inositol 1g twice daily for 6 months) and group B (Tab. Metformin 500 mg thrice daily for 6 months). After taking informed consent, by face-to-face interview, baseline data will be collected consecutively from polycystic ovarian syndrome with the help of a semi-structured questionnaire. Both groups were followed up at the end of the third and sixth months of the whole drug therapy period. The data were analysed via SPSS (version 24.0).
Results: The Mean age of all study subjects was 24.24±3.47 SD (years). Mean Ferriman-Gallwey score and Luteinizing hormone were higher among group B than group A at the end of 6 months (p<0.05). After 6 months of treatment, regular menstrual cycles increased by 38% and 26% (p>0.05) while acne reduced by 26% and 14% in group A and B, respectively (p=0.021). Vomiting, generalised weakness, and flatulence were significantly higher in the metformin group than the myo-inositol group after 6 months (p<0.05).
Conclusion: In the treatment of PCOS patients, myo-inositol is as effective as metformin and has a better safety profile. However, further larger multicenter studies are warranted.
Keywords: Myo Inositol, Polycystic Ovary Syndrome, Metformin
Corresponding Author | How to Cite this Article | To Browse |
---|---|---|
Email: |
, Medical Officer, , UHC, Charghat, Rajshahi, Bangladesh.Karmoker CR, Khatun A, Sarkar AC, Efficacy And Safety of Myo Inositol in The Treatment of Polycystic Ovary Syndrome Patients Comparison with Metformin. Obs Gyne Review J Obstet Gynecol. 2025;11(1):10-20. Available From https://obstetrics.medresearch.in/index.php/joog/article/view/180 |